Exelixis
EXEL
#1537
Rank
NZ$25.30 B
Marketcap
NZ$102.12
Share price
3.01%
Change (1 day)
48.76%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): NZ$5.35

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$5.46. In 2025 the company made an earnings per share (EPS) of NZ$5.05.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$5.356.11%
2025NZ$5.05
2023NZ$1.1414.61%
2022NZ$1.00-22.97%
2021NZ$1.29100%
2020NZ$0.65-65.09%
2019NZ$1.85-53.91%
2018NZ$4.02333.96%
2017NZ$0.93-260.61%
2016NZ-$0.58-58.75%
2015NZ-$1.40-42.45%
2014NZ-$2.435.3%
2013NZ-$2.30

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$15.25 179.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.29-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$25.28 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$4.47-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$6.24 14.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.22 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$6.79 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$41.55-860.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.47-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA